Origin Biotech

Origin Biotech is a clinical-stage biotechnology company focused on developing innovative therapies for chronic liver diseases, with a primary emphasis on achieving a functional cure for Chronic Hepatitis B (CHB). The company's lead candidate, OB-002, is an orally administered Toll-like receptor 7 (TLR7) agonist designed to stimulate the innate immune system to clear the virus. Its pipeline also includes HBV capsid assembly modulators and agents targeting the hepatitis B surface antigen. Headquartered in Beijing with operations in the United States, Origin Biotech leverages its expertise in medicinal chemistry and immunology to address significant unmet needs in hepatology.